Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance

Human Immunology

Volumn 71, Issue 9, 2010, Pages 865-873

  Fury, Wen ^a   Tremoulet, Adriana H ^b,c   Watson, Virginia E ^b   Best, Brookie M ^b,d   Shimizu, Chisato ^b   Hamilton, Jennifer ^a   Kanegaye, John T ^b   Wei, Yi ^a   Kao, Chiayi ^a   Mellis, Scott ^a   Lin, Calvin ^a   Burns, Jane C ^b  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Gene expression; Intravenous immunoglobulin; Kawasaki disease

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTROPHIL COLLAGENASE; PROTEIN S 100; RNA;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTIGENS, CD; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1Q; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GPI-LINKED PROTEINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MALE; MATRIX METALLOPROTEINASE 8; MUCOCUTANEOUS LYMPH NODE SYNDROME; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, INTERLEUKIN-1 TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S100 PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 77956012024     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.06.008     Document Type: Article

References (45)

1. Popper S.J., Shimizu C., Shike H., Kanegaye J.T., Newburger J.W., Sundel R.P., et al. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 2007, 8:R261.
2. Abe J., Jibiki T., Noma S., Nakajima T., Saito H., Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005, 174:5837-5845.
3. Nomura I., Abe J., Noma S., Saito H., Gao B., Wheeler G., Leung D.Y. Adrenomedullin is highly expressed in blood monocytes associated with acute Kawasaki disease: A microarray gene expression study. Pediatr Res 2005, 57:49-55.
4. Ebihara T., Endo R., Kikuta H., Ishiguro N., Ma X., Shimazu M., et al. Differential gene expression of S100 protein family in leukocytes from patients with Kawasaki disease. Eur J Pediatr 2005, 164:427-431.
5. Furuno K., Takada H., Yamamoto K., Ikeda K., Ohno T., Khajoee V., et al. Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease. J Pediatr 2007, 151:155-160. 160e151.
6. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., Colan S.D., Duffy C.E., Fulton D.R., Glode M.P., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
7. Burns J.C., Capparelli E.V., Brown J.A., Newburger J.W., Glode M.P. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998, 17:1144-1148.
8. Tremoulet A.H., Best B.M., Song S., Wang S., Corinaldesi E., Eichenfield J.R., et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008, 153:117-121.
9. Uehara R., Belay E.D., Maddox R.A., Holman R.C., Nakamura Y., Yashiro M., et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008, 27:155-160.
10. Burns J.C., Best B.M., Mejias A., Mahony L., Fixler D.E., Jafri H.S., et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833-838.
11. Kobayashi T., Inoue Y., Takeuchi K., Okada Y., Tamura K., Tomomasa T., et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006, 113:2606-2612.
12. Mori M., Imagawa T., Yasui K., Kanaya A., Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000, 137:177-180.
13. Sano T., Kurotobi S., Matsuzaki K., Yamamoto T., Maki I., Miki K., et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007, 166:131-137.
14. Egami K., Muta H., Ishii M., Suda K., Sugahara Y., Iemura M., Matsuishi T. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006, 149:237-240.
15. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the young, American Heart Association. Circulation 2004, 110:2747-2771.
16. de Zorzi A., Colan S.D., Gauvreau K., Baker A.L., Sundel R.P., Newburger J.W. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998, 133:254-258.
17. McCrindle B.W., Li J.S., Minich L.L., Colan S.D., Atz A.M., Takahashi M., et al. Coronary artery involvement in children with Kawasaki disease: Risk factors from analysis of serial normalized measurements. Circulation 2007, 116:174-179.
18. Singer B.B., Klaile E., Scheffrahn I., Muller M.M., Kammerer R., Reutter W., et al. CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes. Eur J Immunol 2005, 35:1949-1959.
19. Singer B.B., Scheffrahn I., Heymann R., Sigmundsson K., Kammerer R., Obrink B. Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes: Evidence for replacement of the short cytoplasmic domain isoform by glycosylphosphatidylinositol-linked proteins in human leukocytes. J Immunol 2002, 168:5139-5146.
20. Srikrishna G., Panneerselvam K., Westphal V., Abraham V., Varki A., Freeze H.H. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. J Immunol 2001, 166:4678-4688.
21. Takeda K., Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9.
22. Jiang Z., Ninomiya-Tsuji J., Qian Y., Matsumoto K., Li X. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol 2002, 22:7158-7167.
23. Scheper G.C., Morrice N.A., Kleijn M., Proud C.G. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 2001, 21:743-754.
24. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087-6093.
25. Blanco-Aparicio C., Torres J., Pulido R. A novel regulatory mechanism of MAP kinases activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphatase. J Cell Biol 1999, 147:1129-1136.
26. van den Borne S.W., Cleutjens J.P., Hanemaaijer R., Creemers E.E., Smits J.F., Daemen M.J., Blankesteijn W.M. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009, 18:37-43.
27. Popper S.J., Watson V.E., Shimizu C., Kanegaye J.T., Burns J.C., Relman D.A. Gene transcript abundance profiles distinguish Kawasaki disease from adenovirus infection. J Infect Dis 2009, 200:657-666.
28. Ilowite N., Porras O., Reiff A., Rudge S., Punaro M., Martin A., et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009, 28:129-137.
29. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
30. Yang H.H., Kim J.M., Chum E., van Breemen C., Chung A.W. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg 2010.
31. Boyle J.R., McDermott E., Crowther M., Wills A.D., Bell P.R., Thompson M.M. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 1998, 27:354-361.
32. Manning M.W., Cassis L.A., Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003, 23:483-488.
33. Lau A.C., Duong T.T., Ito S., Wilson G.J., Yeung R.S. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 2009, 157:300-309.
34. Abdul-Hussien H., Hanemaaijer R., Verheijen J.H., van Bockel J.H., Geelkerken R.H., Lindeman J.H. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009, 49:741-749.
35. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
36. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
37. Ichiyama T., Yoshitomi T., Nishikawa M., Fujiwara M., Matsubara T., Hayashi T., Furukawa S. NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001, 99:373-377.
38. Sunahori K., Yamamura M., Yamana J., Takasugi K., Kawashima M., Yamamoto H., et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R69.
39. Burns J.C. S100 proteins in the pathogenesis of Kawasaki disease. J Am Coll Cardiol 2006, 48:1265-1267.
40. Hirono K., Foell D., Xing Y., Miyagawa-Tomita S., Ye F., Ahlmann M., et al. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol 2006, 48:1257-1264.
41. Ergun S., Kilik N., Ziegeler G., Hansen A., Nollau P., Gotze J., et al. CEA-related cell adhesion molecule 1: A potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 2000, 5:311-320.
42. Terai M., Yasukawa K., Narumoto S., Tateno S., Oana S., Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999, 83:337-339.
43. Freeman A.F., Crawford S.E., Cornwall M.L., Garcia F.L., Shulman S.T., Rowley A.H. Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium. Pediatr Cardiol 2005, 26:578-584.
44. Tsujimoto H., Takeshita S., Nakatani K., Kawamura Y., Tokutomi T., Sekine I. Delayed apoptosis of circulating neutrophils in Kawasaki disease. Clin Exp Immunol 2001, 126:355-364.
45. Tsujimoto H., Takeshita S., Nakatani K., Kawamura Y., Tokutomi T., Sekine I. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease. Clin Immunol 2002, 103:161-168.